AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

NCT00454805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: AZD2171
DRUG: Fulvestrant

Sponsor

AstraZeneca